Retatrutide
retatrutide
PHASE3
Drug Profile
ModalityPeptide
RouteSC
Therapy AreaCVRM
Peak Sales Est$20000M
Formulations[]
Mechanism: GLP-1/GIP/Glucagon triple agonist
Expert: Triple agonist targeting GLP-1, GIP, and glucagon receptors. Glucagon component adds energy expenditure and hepatic effects beyond dual agonists.
Everyday: Mimics three gut hormones at once for maximum weight loss and metabolic benefits. May achieve weight loss comparable to surgery.
Targets: ["GLP-1","GIP","GCGR"]
Programs (3)
| Indication | Stage | Key Study | Regional Status |
|---|
| MASH | PHASE3 | TRIUMPH-MASH | [] |
| Obesity | PHASE3 | TRIUMPH-1/2/3/4 | [{"stage":"PHASE3","region":"US"}] |
| T2D | PHASE3 | TRIUMPH-DM | [] |
Upcoming Catalysts (4)
Retatrutide - Obesity/CVD - Ph3 - Topline (TRIUMPH-3)
February 2026
Retatrutide - Obesity - Ph3 - Topline (TRIUMPH-1)
April 2026
Retatrutide - T2D - Ph3 - Topline (TRIUMPH-2)
May 2026
Retatrutide - Obesity - NDA Submission
Late 2026
Notes
Up to 28.7% weight loss at 68 weeks. Safety signal: dysesthesia in 8-21% of patients.
Data from Supabase · Updated 2026-03-24